Target type: molecularfunction
Combining with a collagen and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. [GOC:bf, GOC:uh, PMID:21568710]
Collagen receptors are transmembrane proteins that bind to collagen, a fibrous protein found in connective tissues. They play a crucial role in a wide range of biological processes, including cell adhesion, migration, proliferation, and differentiation. Collagen receptor activity is a molecular function that describes the ability of a protein to interact with collagen molecules. This interaction is mediated by specific binding domains within the receptor protein, which recognize and bind to specific epitopes on the collagen molecule.
The binding of collagen to its receptor triggers a cascade of intracellular signaling events, leading to the activation of downstream signaling pathways. These pathways regulate various cellular functions, such as cytoskeletal reorganization, gene expression, and cell survival.
Collagen receptors can be divided into different families based on their structural features and signaling mechanisms. Some of the major families include:
* **Integrins:** Integrins are heterodimeric transmembrane receptors that bind to a wide variety of extracellular matrix proteins, including collagen. They are involved in cell adhesion, migration, and signal transduction.
* **Discoidin domain receptors (DDRs):** DDRs are single-pass transmembrane receptors that specifically bind to collagen. They are tyrosine kinases that activate downstream signaling pathways involved in cell growth, differentiation, and angiogenesis.
* **Leukocyte-associated immunoglobulin-like receptor (LAIR)-1:** LAIR-1 is a transmembrane receptor that binds to collagen and inhibits immune cell activation. It is involved in the regulation of inflammatory responses.
* **Collagen triple helix repeat containing (CTHRC) proteins:** CTHRC proteins are secreted proteins that bind to collagen and modulate its assembly and function.
Mutations in collagen receptors can lead to a variety of diseases, including connective tissue disorders, immune deficiencies, and cancer. Therefore, understanding the molecular function of collagen receptor activity is crucial for developing new therapeutic strategies for these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Platelet glycoprotein VI | A platelet glycoprotein VI that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9HCN6] | Homo sapiens (human) |
Integrin alpha-2 | An integrin alpha-2 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P17301] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
gamma-aminobutyric acid | gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4. gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system. | amino acid zwitterion; gamma-amino acid; monocarboxylic acid | human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule |
losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
valsartan | valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. | biphenylyltetrazole; monocarboxylic acid; monocarboxylic acid amide | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
biphenyl-2-carboxylic acid | biphenyl-2-carboxylic acid: structure in first source | ||
honokiol | biphenyls | ||
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
olmesartan | olmesartan: an active metabolite of CS 866 | biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent |
cinanserin | cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication. Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity. | aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound | anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
exp-3179 | |||
glaucocalyxin a | glaucocalyxin A: chemical constituent of Rabdosia japonica var. glaucocalyx | ||
pci 32765 | ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies. ibrutinib: a Btk protein inhibitor | acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide | antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |
acp-196 | acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity | aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone | antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor |